TrialA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Trial details
- Registry ID
- NCT07065240
- Phase
- Phase 2
SPTX
Seaport Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 | Seaport Therapeutics | Phase 2 | Recruiting | 2027-03Estimated |
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 | Seaport Therapeutics | Phase 2 | Enrolling by invitation | 2027-05Estimated |
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
Trial details
- Registry ID
- NCT07161700
- Phase
- Phase 2
Latest recorded trial changes
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700 · Seaport Therapeutics
Recruitment status changed
− Before
Recruiting
+ After
Enrolling by invitation